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ABSTRACT
The establishment and growth of industrial research laboratories is one of the key organizational
innovations affecting technological progress in the United States in the 20th century. In this paper,
we investigate the rise of industrial research laboratories in the U.S. pharmaceutical industry
between 1927 and 1946. Our evidence suggests that institutional factors, namely the presence of
universities dedicated to research, played a significant role in the establishment and diffusion of
private pharmaceutical research laboratories. Specifically, we document that the growth of industrial
pharmaceutical laboratories between 1927 and 1946 is positively and significantly correlated with
the extent of local university research, after controlling for other observable factors likely to
influence the geographic distribution of industrial research. We supplement our core results with
case histories illustrative of early university-industry interaction and an examination of the
determinants of university-industry research cooperation. Our qualitative historical evidence and
analyses of the birth of chemical engineering programs suggest that industry also played a role in
influencing university research agendas. We correct for feedback effects from industry to
universities using instrumental variables. Overall, our analyses suggest that while the presence of
industrial facilities helped shape the direction of university research programs, there was a
significant, positive, and causal effect running from university research to the growth of















The establishment and growth of industrial research laboratories is one of the key 
organizational innovations affecting technological progress in the United States in the 20
th 
century (Mowery, 1990).  We investigate in this paper the rise of industrial research 
laboratories in the U.S. pharmaceutical industry between 1927 and 1946.  Our evidence 
suggests that universities played a significant role in the establishment and diffusion of 
industrial research laboratories in the U.S. pharmaceutical industry during this period.  The 
foundation of our quantitative analysis is the demonstration that the emergence and growth 
of private pharmaceutical research laboratories depends upon the extent and growth of 
nearby academic science.  We complement the quantitative results with qualitative evidence 
that elucidates some of the mechanisms by which universities and industry interacted during 
this period.  For example, our qualitative analyses demonstrate evidence of university-
industry collaboration involving prominent academics, considerable academic participation 
in industrial patenting, and the staffing of emerging industrial research laboratories with 
graduates of nearby university programs.  We are also alert to the fact that this relationship 
may not have been unidirectional, and devote particular attention to the possibility that the 
local industrial base affected the nature of academic science at universities during this 
period.  Our analyses provide suggestive though not dispositive evidence of the impact of 
local firms on university programs.  Even when we correct for this endogeneity bias, 
however, the result that laboratory births are positively related to PhD program graduates 
remains.  We interpret this combination of qualitative and quantitative evidence as support 
for the hypothesis that universities played a significant role in the birth of early American 
pharmaceutical research laboratories.   2
Hand-in-glove relationships between firm laboratories and universities in the life 
sciences are commonplace in the early 2000s, but were substantially more rare a century 
ago.  Indeed, many academic scientists and academic bodies viewed industry with extreme 
skepticism or overt antipathy.  Quoting a 1915 report of the Committee of the Board of 
Trustees of the American Medical Association, Parascandola (1985) illustrates the contempt 
held by medical scientists for industry:  “It is only from laboratories free from any relations 
with manufacturers that real advances can be expected.”
1  Though a fictional tale, Sinclair 
Lewis’s novel Arrowsmith is more severe but also representative of the attitude of the time.  
Reacting to the news of famed biology professor Max Gottlieb’s decision to join the 
research laboratories of a private firm, colleagues grieved:  In one lab, “sorrowing men 
wailed, ‘How could old Max have gone over to that damned pill peddler?,’” while in other 
places colleagues lamented, “Of all the people in the world! I wouldn’t have believed it! 
Max Gottlieb falling for those crooks!,” and “I wish HE hadn’t gone wrong!” (Lewis, 1925, 
p. 52).
2  It is, then, somewhat surprising that an environment that harbored such scorn for 
industry would, ultimately, be actively involved in planting the seed corn for the 
development of industrial research laboratories. 
History demonstrates, however, that Prof. Gottlieb’s decision to work with the pill 
peddlers was emblematic of the growing ties between university scientists and private firms 
in the U.S. pharmaceutical and chemical industries during this time period.  Indeed, while, 
“American drug companies by and large had no interest in research [in the early years of the 
20
th century,]” (Swann, 1990, p.77), industrial research laboratories grew throughout the 
                                                 
1  This quote appears in the Journal of the American Medical Association (1915) “Special Report of the Work 
of the Council on Pharmacy and Chemistry,” 65, p. 69. 
2  This quote is used commonly among historians of the U.S. pharmaceutical industry to reflect the attitudes of 
the time.  See, for example, Parascandola (1985), Swann (1990), and Liebenau et al. (1990).    3
1920s and 1930s such that they were a common organizational form among large 
pharmaceutical manufacturers by the time of World War II.  The increasing relevance of 
academic science for industrial purposes in the late 19
th and early 20
th centuries appears to 
have been a principal underlying force that enabled collaborations between universities and 
industry to be ultimately fruitful (Mowery and Rosenberg, 1998; Murmann, 2003).  We 
argue that the existence of U.S. universities (and their specific form and nature) animated 
the potential for interaction between academic scientists and pharmaceutical firms in the 
U.S. interwar period.  We examine the early mechanisms through which universities 
affected research in the pharmaceutical and chemical industries and devote particular 
attention to the labor market for trained researchers, collaborative research and consulting 
agreements, and contract research arrangements.
3  While our primary aim is to ascertain the 
extent and nature of university influence on the development of industrial research 
laboratories, we also examine the extent to which university researchers and their 
institutions were affected by their interactions with industry.  Some qualitative evidence 
suggests that large pharmaceutical companies with substantial research needs did, indeed, 
influence proximate universities, and our statistical analyses provide some evidence 
consistent with this phenomenon.  
In our principal analysis, we assesses the relationship between academic science and 
the establishment of pharmaceutical research laboratories by estimating the impact of the 
presence of universities and the count of PhD graduates on the number of industrial 
pharmaceutical laboratories established and number of pharmaceutical R&D workers in 
geographically proximate areas.  We set the stage for this analysis by reviewing case 
                                                 
3 The importance of collaborative research between academic scientists and drug makers is of central interest in 
the industrial histories of John P. Swann (1988, 1990).   4
histories of early U.S. pharmaceutical firms and describing the nature of relationships 
between academic scientists and pharmaceutical firms.  The empirical evidence reveals that 
pharmaceutical labs were more likely to be located in counties that contained research in 
academic chemistry or science.  Specifically, the number of pharmaceutical laboratories in a 
county in 1938 and 1947 is, across a wide range of specifications, positively and 
significantly associated with the initial number of research laboratories and the 
contemporaneous count of local science PhD graduates.   
Building on the quantitative analyses, we clarify some of the mechanisms by which 
universities appear to have influenced the birth of pharmaceutical research laboratories.  In 
particular, drawing on records from the rosters of Who’s Who in Chemistry (1928), we 
demonstrate the involvement of adopting firms in the labor market for graduating PhDs.  
Further, we present evidence that collaborative arrangements between academic scientists 
and industry and, occasionally, contract research agreements were both important pre-
cursors and complements to firms developing their own laboratories.  Combining patent data 
with data from American Chemical Society membership rosters, we find that a substantial 
share of pharmaceutical patents for which we can identify inventor affiliations included 
academic inventors. 
Overall, our results paint a picture in which the role of universities in the 
development of industrial research laboratories is significant and multifarious.  In addition to 
serving as the launching pad for the careers of individuals who found employment in private 
firm laboratories, U.S. universities appear to have played a role in the creation of such 
laboratories, via collaborative research and consulting, and in their developing expanded 
research capabilities over time.  We also cite qualitative evidence of feedback effects from   5
firms to universities.  By both providing financial support for university research 
laboratories and a market for future trained labor, firms supported the growth of scientific 
capabilities at local universities. The relationships between Merck and Rutgers and Dupont 
and the University of Delaware are illustrative of the bi-directional impact of the 
relationship between universities and industry.  Our analysis of the birth of chemical 
engineering programs provides evidence consistent with these qualitative accounts.  Our 
core results about the influence of universities on the birth of research laboratories do, 
however, hold up, even after correcting for endogeneity using instrumental variables. 
The remainder of the paper proceeds in the following way:  Section 2 introduces 
background research on university-industry interaction and reviews the history of the 
pharmaceutical industry in the early 20
th century, and the origins of industrial research 
laboratories.  Section 3 reviews historical interactions between the U.S. pharmaceutical 
industry and academic science.  Section 4 describes our core dataset.  Section 5 evaluates the 
importance of universities in influencing the growth of pharmaceutical research laboratories.  
Section 6 assesses the mechanisms of interaction between universities and pharmaceutical 
firms in greater detail.  Section 7 reviews quantitative evidence on the role of industry in 
affecting program births in universities.  Section 8 discusses our instrumental variables 
estimates.  Section 9 concludes, discussing the implications of the results and speculating 
regarding related, future research. 
 
II.  University-Industry Interaction and the Origin of Industrial Research 
Laboratories 
In this section, we lay the groundwork for our argument that U.S. universities 
contributed to the establishment and growth of industrial research laboratories.  In particular,   6
we review research that describes the growth of the U.S. universities in the late 1800s and 
early 1900s, suggests the importance of universities to the United States’ emerging industrial 
leadership, and suggests that proximity and specific institutional arrangements played an 
important role in university-industry interaction. 
 
II.1  The emergence of U.S. universities and the nature of university-industry interaction 
Goldin and Katz (1999) identify the period of 1890-1940 as the “formative years” of 
American higher education.  States dramatically increased their support of higher education 
during this period and the U.S. research university emerged in a form similar to that which 
exists today.  These years were also formative for university-industry collaboration and the 
rise of industrial research laboratories in the United States.  Figures 1-3 display the number 
of public universities, private universities, and industrial research labs by founding date, 
beginning in 1830.  They reveal that more universities were founded in the late 19
th century 
than in any other period.  In large part, the rise of universities was due to the Morrill Act of 
1862, which established the land-grant universities, and the Hatch Act of 1887, which 
provided aid for the study of scientific agriculture.  The emergence of industrial research 
labs came somewhat later, in the 1920s and 1930s.
4  The boom during this period was, 
however, quite substantial, so substantial in fact that university-industry interaction reached 
a high point in the period between World War I and World War II.  As Mowery and 
Rosenberg (1998) note, “university-industry research linkages… were well-established 
                                                 
4  It should be taken into account that these graphs are snapshots taken at two different points in time: the 
university data were compiled in 1924 and the industrial research lab survey was conducted in 1946. As a 
result, firms that were founded prior to 1946 but did not survive to that date are not counted.   7
before World War II.  Indeed, the share of university research expenditures financed by 
industry appears to have declined throughout much of the postwar period” (p. 37).
5 
Rosenberg, Mowery, Nelson and a number of co-authors have argued that the 
research universities that emerged during this period – and, in particular, the aspects of 
academic science that responded to the needs of industry – became one of the main drivers 
of American technological leadership in the twentieth century.
6  These authors note a 
number of examples of commercially important early inventions that originated in 
universities, including the Babcock test (which improved the way dairy producers tested the 
butterfat content of milk); Edwin Armstrong’s research on vacuum tubes at Columbia 
University (which influenced the development of radio technology); and the development of 
hybrid corn at agricultural experiment stations.
7  Noting the important influence on 
innovation in the later part of the 20
th century, these authors further acknowledge the 
seminal contributions of university research on the development of computers and lasers 
(Rosenberg and Nelson, 1994; Mowery et al., 2003, p. 1). 
The role of proximity in facilitating university-industry linkages is central in our 
investigation of the factors that led to the rise of industrial research laboratories.  Existing 
empirical studies of contemporary university-industry research linkages suggest that 
research conducted in universities has a significant and geographically focused effect on 
innovation.  Jaffe (1989) provides evidence that corporate patenting in certain industries is 
                                                 
5  Also, Swann (1988) argues that post-war increases in federal funding for university research in the health 
sciences reduced collaboration between universities and the pharmaceutical industry. 
6  See Nelson and Wright (1992), Rosenberg and Nelson (1994), Mowery and Rosenberg (1998), Rosenberg 
(2000), Mowery, Nelson, Ziedonis and Sampat, (2003). 
7  As another example, the University of Akron supplied local rubber producers with skilled employees, and its 
scientists conducted research in the processing of rubber and, later, polymer chemistry (Mowery et al., 
2003), p. 1).  Additional examples include the University of Oklahoma’s research in the field of petroleum, 
the University of Kentucky’s and the University of North Carolina’s focus on the processing of tobacco, and 
the University of Illinois and Purdue University’s work on railroad technologies (Nelson and Rosenberg, 
1994).      8
positively associated with state-level spending on university research in related academic 
disciplines. Acs, Audretsch and Feldman (1992) substitute innovation counts for patent data 
and find even stronger evidence for spillovers from university research. Jaffe, Trajtenberg, 
and Henderson (1993) find that knowledge spillovers from university research, as measured 
by patent citations, are geographically concentrated.
8  In a study of the biotechnology 
industry, Zucker, Darby and Brewer (1998) show that biotechnology firms tend to locate 
near universities in order to take advantage of the areas’ higher levels of “intellectual 
capital”.  In both the qualitative and quantitative evidence we review, geographic proximity 
plays an important role in facilitating interactions between universities and pharmaceutical 
firms. 
The nature of university-firm interactions is informed by research that examines the 
organizational locus of innovative activity.  Specifically, a set of recent papers examine 
whether innovative activity takes place in divisions of the corporation or in entrepreneurial 
firms that transact in the market for technology.  Teece (1988) explains how transaction 
costs can dictate the organizational form in which innovation takes place.  Arora, Fosfuri 
and Gambardella (2001) document the growth in technology trade in the late twentieth 
century, led by high-tech industries like software, chemicals, semi-conductors and 
electronics.  Arora, Fosfuri and Gambardella (2003) model the division of “inventive labor” 
under different conditions.  Stern and Gans (2003) focus on how several aspects of the 
“commercialization environment” affect the innovative start-up’s optimal choice of co-
operation or competition with incumbent firms.  Peretto (1998) develops a model that 
explains the transition from independent inventors to corporate R&D labs in the late 
                                                 
8 Patent citations are references in the patent document to other patented technologies that bear a similarity to 
the invention or that influenced the inventor.  Note that Adams (2002) also finds evidence of geographically-
mediated university spillovers.   9
19
th/early 20
th centuries as a product of the “interaction of market structure and 
technological change.” 
 
II.2  The origins of industrial research 
The first organized industrial research laboratories appeared in Germany in the 
1870s, in firms that sought to commercialize inventions based on recent breakthroughs in 
organic chemistry (Mowery and Rosenberg, 1998, p. 13.).  Murmann (2003) describes the 
co-evolution of the dye industry and academic research in chemistry in nineteenth-century 
Germany, and argues that spillovers from universities to the dye industry and vice versa led 
Germany to dominate the international dye industry in the 19
th century.  Mowery and 
Rosenberg argue that it was not scientific developments alone which led to the growth of in-
house research in the United States, but also the strength of U.S. anti-trust policy following 
the Sherman Act (which triggered a search for alternative sources of market power through 
industrial innovation) and stronger protection of intellectual property rights through the 
patent system.  However, as Mowery points out, “a weak antitrust climate in other nations, 
such as Germany, was associated with growth in industrial research, making it difficult to 
assert a direct cause-and-effect relationship between anti-trust policy and the growth of 
intrafirm R&D” (Mowery, 1990, p. 346).  It could also be argued that the increasing strength 
of intellectual property rights in the late 19
th and early 20
th centuries would seem to promote 
greater specialization in innovation and vertical dis-integration rather than a shift in 
innovative activity from the realm of the independent inventor to within the boundaries of 
the corporation.  Indeed, Lamoreaux and Sokoloff (2002) argue that, in the nineteenth 
century,   10
“the U.S. patent system created a framework that supported trade in technology, 
and that the patent agents and lawyers who serviced this system often took on the 
functions of intermediaries, matching inventors seeking capital with investors 
seeking profitable outlets for their funds and also inventors seeking to sell new 
technological ideas with buyers eager to develop and commercialize them” (p. 5-
6). 
 
Lamoreaux and Sokoloff (1996) document a well-functioning market for technology in the 
late nineteenth century United States.  In 1870-71, for example, 72% of all patents that were 
assigned to a party other than the inventor were assigned after issue.  By 1910-11, this 
number was halved (36.5%).  Fisk (1998) explains that, prior to the 1890s, courts almost 
always favored the rights of the inventor in cases where the ownership of an employee’s 
invention was contested by an employer.  Starting in the 1890s, Fisk documents the 
emergence of the “shop right” patent doctrine, which favored the employer in intellectual 
property disputes.  This change in intellectual property doctrine no doubt made it much more 
attractive for firms to establish in-house research labs. 
Mowery and Rosenberg also emphasize the importance to industrial innovation of 
science conducted in universities.  In this paper, we argue that the unique form taken by 
American universities in the late nineteenth and early twentieth centuries helped promote the 
adoption of industrial research laboratories within the boundaries of firms.  Whereas during 
the nineteenth century, “most industrialists believed the manufacturer’s job was to 
manufacture; new ideas to improve manufacturing could be purchased or otherwise 
appropriated … managers offered little support for research until they had evidence that a 
worker’s results indicated likely commercial application,” (Swann, 1988, p. 13) the 
institutionalization of scientific research in universities facilitated the adoption of scientific 
research in industry.  The scientific research undertaken in universities reduced the cost to 
firms of acquiring scientific knowledge, and this led firms located near universities to   11
engage in research.  Furthermore, the trend towards specialization and professionalization in 
science increased the supply of qualified workers with easily identifiable skills.  Once firms 
could access a pool of potential research workers whose academic credentials reduced the 
uncertainty associated with hiring them, firms could establish labs to engage in long-term 
research projects. 
Several interrelated historical forces combined to favor the organization of invention 
within the firm.  Changes in the nature of technology, in the extent to which firms could 
claim intellectual property rights over their employees’ inventions, and in the enforcement 
of anti-trust rules contributed to firms seeking to adopt of in-house industrial research 
facilities.  In order for firms to respond to these forces to organize invention within firm 
boundaries, they needed skilled R&D workers and scientific expertise.  Universities 
provided these inputs to production of new technology through consulting relationships and 
by providing certification for the skills of potential R&D employees. 
 
III.  The U.S. Pharmaceutical Industry and Academic Science in the Early 20
th 
Century 
III.1.   Research in the pharmaceutical industry in the early 20
th century 
Although a select number of pharmaceutical firms employed in-house researchers in 
the early years of the 20
th century, the period between the 1920 and World War II witnessed 
a substantial change in the organization and function of U.S. drug makers (Swann, 1988).  
Over this period, the industry changed from consisting of nearly entirely manufacturing-
oriented firms to being largely comprised of firms dedicated to the systematic discovery and 
introduction of efficacious medicines.  Some of the changes in the industry were preceded or 
accompanied by legislative changes, such as the Biologics Control Act of 1902 and Pure   12
Food and Drug Act of 1906 (and 1912 Shirley Amendment), each of which pushed the 
industry away from sometimes fraudulently-labeled ‘patent’ medicines towards more 
rationalized practices. 
In addition to US-based characteristics and policies, Europe played an important role 
in aiding American firms in their transition to science-based pharmaceutical research.  In the 
years prior to World War I, European-trained (mainly German-trained) researchers and 
students returned to the United States, often to Philadelphia, New York, and the region in-
between (Feldman and Schreuder, 1996) offering expertise, particularly in biologics, to 
pharmaceutical firms, universities, and public health administrations.  The development of 
research capabilities in U.S. pharmaceutical firms was further accelerated by World War I.  
The loss of access to European medicines increased the need for national medicine-making 
capabilities, and the ability to develop medicines was enhanced both by European 
immigration and by the seizure and auction of German intellectual property by the Office of 
the Alien Property Custodian. 
These developments were concomitant with an increasing relevance of academic 
science for drug-making during late 19th and early 20th centuries, which in the eyes of 
Mowery and Rosenberg (1998) and Murmann (2003) helped set the stage for fruitful 
collaborations between universities and industry and, as we argue, for the US 
pharmaceutical industry to draw on resources in universities to help develop in-house 
research facilities.  From the early part of the century, during which research and 
development expenditures were minimal, Mahoney (1959, p. 4) reports that research 
expenditures increased to $15 million in 1939 and $110 million by 1956.  Mahoney claims 
that the nature of the pharmaceutical industry changed dramatically during the 1930s and   13
1940s, as a result of increasing average firm size and technical sophistication.  For example, 
he reports that during the depression years of 1932 and 1934, more than 3,500 firms failed 
(p. 4) and that even until the 1940s most firms were quite small:  “As late as 1939 no ethical 
drug manufacturer in America had a sales volume as large as a department store like Macy’s 
in New York” (p. 4). 
Although the nature of the industry was already changing by the early 1940s, the 
loss, once again, of medicines from Europe and the exigencies of war prompted significantly 
increased investment in research during World War II.  For the first time, the U.S. 
government became actively involved in promoting drug development and manufacturing.   
Two major projects in which the government played a large role were the production of 
penicillin and dried plasma.  These projects were mainly dedicated towards large-scale 
manufacturing, but significant R&D capabilities were a pre-requisite for achieving the 
knowledge to effectively produce the products, and those firms that had already achieved 
some level of in-house research expertise were at considerable advantage. 
 
III.2. Historical  evidence  of the influence of early 20
th century academic science on 
pharmaceutical research 
In order to characterize the relationship between academic science and the early 
industrial research labs, we exploit the fact that geographic proximity facilitates interaction 
between people and organizations.  We argue that firms located near research universities 
were more likely to adopt in-house R&D facilities because local universities provided both 
part-time faculty consultants with highly specialized knowledge and scientifically-trained 
university graduates who could be employed as full-time research employees.  Because 
long-distance collaboration was more difficult in the first half of the twentieth century than   14
it is today, firms were more likely to focus their search for scientific expertise on nearby 
institutions.  In this section, we discuss histories of a number of early pharmaceutical firms, 
including Mulford and Sterling, whose cases appear illustrative of the influence of local 
university science on firm-specific investments in innovation.
9 
III.2.1 Illustrative Cases – Mulford & Sterling at the turn of the 20
th century 
Founded by two graduates of the Philadelphia College of Pharmacy, the H.K. 
Mulford Company commenced operations in Philadelphia in 1891 when H.K. Mulford and 
Milton Campbell purchased the “Old Simes” drugstore.  After initial successes in improving 
pill-making technologies, the founders undertook a more ambitious challenge for which they 
themselves were by no means sufficiently trained – the synthesis of diphtheria antitoxin.  
Bacteriological illness had become increasingly problematic for urban areas as a result of the 
increased density of city life.  This problem was of particular concern to the Municipal 
Health Department in Philadelphia, which was the third largest city in the country at the 
time.  Philadelphia’s Health Department, like that of New York, was especially active in 
promoting efforts to address bacteriological illnesses.  Long known as the “Cradle of 
Pharmacy” (Mahoney, 1959; Feldman and Schreuder, 1996), Philadelphia was the home to 
some of the most advanced biomedical research institutions in North America.  In addition 
to the Philadelphia College of Pharmacy, several other institutions were pursuing 
bacteriological research, including the University of Pennsylvania, Medico-Chirurgical 
College, and Pepper Clinical Laboratories of the University Hospital.  Together with the 
Municipal Health Department, these institutions were engaged in research on diphtheria in 
response to “public clamor” for a diphtheria antitoxin (Galambos, 1995, p. 13).  Galambos 
                                                 
9 Furman (2003) reviews the relationship between local resources and the strategic orientation of Mulford and 
Sterling.   15
argues that Mulford “recognized the opportunities embodied in the “clamor” for diphtheria 
antitoxin” and set out to produce a commercially viable drug (Galambos, 1995, p. 13).  In 
1894, the firm hired Dr. Joseph McFarland, who was on faculty at the University of 
Pennsylvania’s Medical Department and the Philadelphia Polyclinic and College for 
Graduates in Medicine and had trained in bacteriology in Heidelberg and Vienna, and 
created for him a laboratory in which he could concentrate on developing diphtheria 
antitoxin (Galambos, 1995).  In his efforts, McFarland benefited greatly from interactions 
with the New York City Health Department and the Laboratory for Hygiene at the 
University of Pennsylvania.  By 1895, Mulford was able to become the first commercial 
provider of a diphtheria anti-toxin.  The firm’s success with McFarland then led them to hire 
Professor Leonard Pearson from Penn’s Veterinary School and to establish a full-fledged 
laboratory in 1896 in Glenoden, PA dedicated to biological, veterinary, and vaccine research 
(Galambos, 1995).  In the absence of these locally-available academic scientific resources, it 
does not appear as if Mulford would have engaged the task of synthesizing diphtheria 
antitoxin or, ultimately, of founding a dedicated research laboratory. 
The Sterling pharmaceutical company was founded under circumstances similar to 
those of Mulford and around the same point in time, yet it pursued a very different trajectory 
with respect to research.  Upon graduation from the Philadelphia College of Pharmacy, the 
same institution attended by the founders of Mulford, William E. Weiss returned to his 
hometown of Wheeling, West Virginia and founded the company that became Sterling in 
conjunction with his childhood friend Albert Diebold.  Like Mulford, the fledgling 
drugmaker met with considerable success; unlike Mulford, however, the firm succeeded at 
marketing and distributing patent medicines, products of questionable medical validity   16
which were often alcohol- or narcotic-based.  By 1912, it was valued at $4 million (Mann 
and Plummer, 1991).  In the wake of World War I, Sterling acquired the assets of the Bayer 
Company, including all U.S. rights to Bayer Aspirin in the auction of seized German 
property rights held by the Office of the Alien Property Custodian.  That the fact that 
Sterling was able to raise the funds required for this acquisition demonstrates the triumph of 
the firm’s marketing and distribution resources.  Its technical and research capabilities were 
substantially less well-developed, however.  Sterling’s drug-making competence was, in 
fact, so limited that it was forced to solicit substantial guidance from Bayer in order to have 
any chance to manufacture the basic products it won at auction. 
Both demand and supply side factors appear to have had an influence on Sterling’s 
choice of organizing strategies.  Serving the mainly rural populations of West Virginia and 
central and western Pennsylvania, Sterling did not face substantial demand for medicines to 
fight the bacteriological illnesses towards whose cures academic science had begun to work.  
Even if such demand had existed, however, Sterling did not have ready access to trained 
individuals who could have contributed to effectively to drug discovery; at the very least, it 
seems fair to say that the comparative advantage of Sterling’s West Virginia location was 
not based in scientific research. 
While stylized, these stories seem to be illustrative rather than unique. The early 
history of Detroit’s Parke-Davis, another one of the first chemical firms to establish science-
based industrial research, resonates with that of Mulford.  Similar to its Philadelphia 
counterpart, Parke-Davis began serious research efforts with the aim of making diphtheria 
anti-toxin.  To do so, it hired Elijah M. Houghton, a research assistant at the nearby 
University of Michigan in 1895 and Charles McClintock, a research assistant in   17
bacteriology, in 1896 (Swann, 1988).  Parke-Davis established a research lab in biology, and 
succeeded in producing diphtheria anti-toxin within a few months.  McClintock then turned 
his efforts to other biological research, which dominated the firm until the 1920s when a 
separate department for chemical research was established (Swann, 1988). 
These early examples of the importance of local labor markets in diffusing 
biomedical research knowledge are typical of the experience of U.S. firms in the 1920s and 
1930s.  Firms located near universities appear to have had greater ease in recruiting scholars 
for their research efforts.  The differences in the strength and relevance of the science bases 
in Philadelphia, PA and Wheeling, WV during the formative years of Mulford and Sterling 
are vast.  The “Cradle of Pharmacy,” Philadelphia was home to numerous universities with 
departments dedicated to biomedical sciences, including the University of Pennsylvania 
(which was founded 1740, and offered its first doctorate in 1871), as well as the Philadelphia 
College of Pharmacy (founded 1821), the Medical College of Pennsylvania (1850), 
Jefferson Medical College (1825), Hahnemann Medical College (1848), Temple University 
(1884), and the Drexel Institute of Technology (1892).  The University of Pennsylvania was 
one of the country’s leading biomedical institutions, and had granted, on its own, 919 
doctorates by 1925.  By contrast, Sterling’s hometown, Wheeling, WV was 50 miles from 
the nearest university.  The closest large universities to its home base were in Pittsburgh (59 
miles from away), Morgantown, WV (79 miles away), and Penn State (198 miles away).  
Though not immediately nearby, Pittsburgh was an emerging center of university life at the 
turn of the century, offering the University of Pittsburgh (which was founded in 1786 and 
granted its first doctorate in 1886), the Carnegie Institute of Technology (founded 1905), 
and Duquesne University (founded 1878).  However, even if Sterling had opened facilities   18
in Pittsburgh, these growing universities would not have been able to offer research services 
comparable to those of Philadelphia – by 1925, the city’s largest university, the University 
of Pittsburgh, had only granted 86 PhDs, and Carnegie and Duquesne did not grant any 
PhDs until the 1920s. 
III.2.2.  Early university-industry interactions - collaborations & local labor markets 
In this section we review historical evidence that suggests that university academics 
were sought-after collaborators for early research labs, and that suggests that geographic 
propinquity played an important role in the ability to collaborate with university-based 
researchers.  Both the importance of some academic collaborators and the potentially 
prohibitive cost of long-distance collaboration are illustrated by the agreement struck 
between Du Pont and consulting chemist Roger Adams, a professor at the University of 
Illinois. Du Pont offered Adams $5,000 a year, which was substantially more than half his 
university salary, to entice him to make a monthly trip from Urbana to Wilmington, and to 
visit for a month or so during the summers.  Adams negotiated a deal in which he received 
$3,000 annually (plus travel expenses) for a visit every other month, along with $750 for 
each summer month spent at Du Pont (Hounshell and Smith, 1988).
10  While Du Pont, one 
of the first and most successful companies to adopt in-house research, had access to the 
funds required to invest in long-distance relationships with consultants (and had little choice, 
given the absence of a major research university in the vicinity of Wilmington), younger and 
smaller firms did not.  Table 1 lists the industrial labs in the National Research Council 
(NRC) data that in 1938 listed the names of the universities at which they funded consultants 
                                                 
10 While a consultant for Du Pont, Adams told a colleague, “I feel that I get quite as much out of the contact 
from the chemical standpoint as they do” (Ibid, p. 298).   19
or research fellows.
11  Local universities, where they exist, predominate.  While other more 
distant universities were supported by firms with larger research efforts (like Merck, with a 
research staff of 111), even these firms continue to be associated with nearby universities. 
  Universities, in addition to providing consulting services, fed the labs with a supply 
of skilled labor.  We have seen that Mulford and Parke-Davis both hired graduates of local 
universities (the University of Pennsylvania and the University of Michigan, respectively) to 
form two of the first in-house research labs in the United States.  Looking at a larger sample, 
we draw on evidence of the geographic mobility of university graduates from the Chemical 
Who’s Who, a directory published in 1928 that contains biographical sketches of executives 
and researchers in the chemical industry.  For a sample of the thirty largest labs in the 
National Research Council (NRC) volume of 1927, we collected information on the 
educational background and location of first employment of executives listed in the Who’s 
Who.  Many of the executives, whether directly involved in research or not, came from 
scientific backgrounds, and the biographical information on the location of an individual’s 
alma mater and post-graduate employment is instructive whether or not the individual joined 
the company immediately upon graduation.  The information we collected revealed that the 
first employment after graduation from a university was very often in the same city as the 
university, and that many firms seemed to hire graduates of nearby universities.  While the 
extent of this practice varied by firm, the firms that did hire from nearby universities 
(“nearby” defined loosely to include universities within 100 or 200 miles of the lab) tended 
to hire almost exclusively from those universities.  For example, at Sharp and Dohme of 
Baltimore, one of the two directors of pharmaceutical research listed in the Who’s Who in 
                                                 
11 In the NRC publication, this is described as “grants to university labs for research projects in support of 
program of association.”   20
1928 was J.C. Krantz, a former professor at the University of Maryland and a former 
lecturer at Johns Hopkins.  The other director of pharmaceutical research graduated from the 
Philadelphia College of Pharmacy and had worked at Mulford and Co. in Philadelphia 
before joining Sharp and Dohme.  One laboratory superintendent (C. Neal) was a graduate 
of the University of Maryland department of Pharmacy, and another superintendent (E. 
Miller) earned a doctorate from Johns Hopkins.  Of the nine employees and executives 
whose educational credentials are described in the Who’s Who, six joined after studying or 
working at Johns Hopkins or the University of Maryland.  Three were graduates of the 
Philadelphia College of Pharmacy (two of whom came to Sharp & Dohme after initial 
employment at Mulford & Co) and one came to Sharp & Dohme after working as a 
professor at the University of Vermont.
12 
Another example of localization in early research collaborations, Eli Lilly & Co., of 
Indianapolis, Indiana, engaged in collaborative research with Purdue University.  Lilly hired 
Purdue grads, like director of research development H.W. Rhodehamel, chief pharmacist 
F.E. Bibbins, and assistant chief engineer J.C. Siegesmund.  Pharmaceutical research 
scientist E.H. Stuart was a graduate of Indiana University.  The majority of Lilly employees 
whose credentials are listed in the Who’s Who were graduates of Indiana universities.  Of the 
ten listed university-educated employees of Eli Lilly & Co. of Indianapolis, four were 
graduates of Purdue University (62 miles away in West Lafayette) who joined Lilly upon 
graduation.  Two attended other universities in Indiana (DePauw and Indiana University), 
one came from the U.S. Industrial Alcohol Co. in New Orleans after graduating from 
Louisiana State University, and the others studied at Trinity College and the Philadelphia 
                                                 
12 Sharpe and Dohme acquired Mulford around this time (officially, 1929; Galambos, 1995) , which may  
explain the number of Sharpe and Dohme executives that Who’s Who credits with Mulford experience.    21
College of Pharmacy.  As we discuss in some more detail below, Lilly also provides an 
interesting example of early firms’ abilities to work with distant researchers. 
At Abbott Labs of Chicago, the president, Alfred Burdick, was a former professor at 
the Illinois Medical College; consulting scientist Roger Adams was chair of the department 
of Chemistry at the University of Illinois Urbana-Champaign.  Adams’ former student, 
Henry Volwiler, chief chemist in 1928 (later president and chairman of the board), was a 
graduate of the University of Illinois, as was Floyd Thayer, a former research chemist who 
was in 1928 manager of the chemical sales department.  Of the eight people listed, six joined 
the firm after graduating from or working at an Illinois university.  Swann notes that several 
of Adams’ students also went on to join Abbott (1988). 
In contrast to these examples, there are fifty-five individuals listed as employees of 
Du Pont, and the list of universities is almost as long.  It is clear that not every firm in the 
industry hired graduates of local universities – mainly because it was not always the case 
that local universities produced graduates with the skills required during this period.   
Although the Who’s Who was published in 1928, most of the individuals who appear in it 
had been with the firms for many years, most of them having been hired in the previous 
decade or earlier. 
The example of Alfred Newton Richards’ work for Merck provides one example 
how academics played active roles in the establishment of in-house R&D labs.  Richards 
essentially acted as a head-hunter and recruiter when Merck set up its in-house facilities 
starting in 1930.  Richards was professor of pharmacology and vice-president of medical 
affairs at the University of Pennsylvania.  As Swann notes, “The University of Pennsylvania 
was a logical site for Merck to establish connections for biomedical research and clinical   22
investigations of its drugs.  Pennsylvania was a major research institution with access to 
extensive clinical facilities; the university was conveniently located not far from Rahway; 
and most important, Merck had close contact with one of the faculty whom the university 
community esteemed – Newton Richards” (Swann, 1988, 74-75).  Richards acted as a 
liaison between Merck and the academic community, helping not just in recruiting but also 
in the organization of collaborative projects.  Students and clinicians at Penn carried out the 
investigation and testing of methylcholine, a vasodilator eventually marketed by Merck as 
Mecholyl Chloride.  Pharmacologists at Penn also helped develop Vinethene, an anaesthetic 
originally discovered by a pharmacologist at the University of California Medical School.  
Merck “did not feel that it would be advantageous to spend a great deal of money for the 
pharmacological study of vinyl ether in California.  The distance was so great that a true 
cooperation could not be obtained.”
13  Instead, the work was undertaken by clinical faculty 
at the more geographically proximate University of Pennsylvania.  
  While firms with larger R&D budgets often engaged academic consultants at more 
distant universities who were specialists in a specific field, younger and smaller firms appear 
to have been more likely to collaborate with local academics.  Starting in 1925, 
Northwestern University chemist Arthur Tatum did routine testing a few times a year for the 
small Chicago firm Cook Laboratories.  Tatum had no unique knowledge of the drugs he 
tested, and Swann notes that “Cook probably engaged Tatum simply because of his 
proximity to the firm” (Swann, 1988, p. 103).  Selman Waksman worked part-time at nearby 
Cutter Laboratories while a graduate student at UC Berkeley and at Takamine Labs of New 
Jersey while a young assistant professor at Rutgers (Israel, 2004). 
                                                 
13 Letter from Merck scientist R.T. Major to A.N. Richards, quoted to Swann, 1988, p. 77.   23
Geographic proximity appears to matter most for (a) labs at early stages of 
development, or (b) relatively informal or occasional consulting contracts on general 
scientific matters, but not large-scale research projects requiring specialized scientific 
knowledge.  For example, Lilly had 4 general consultants at nearby universities by 1943: an 
organic chemist from U Chicago ($2000/yr), chemical engineer from Purdue ($600/yr), 
biochemist from U Illinois ($600/yr), organic chemist from U Indiana ($2,400/yr) (Swann, 
1988, p. 52).  However, Lilly’s large-scale collaborative research projects were undertaken 
with researchers at more distant universities, for example their collaboration with Banting 
and Best’s work on synthesizing insulin at the University of Toronto, and with scientists at 
Harvard and the University of Rochester on the treatment of pernicious anemia in the 1920s 
(Swann, 1988, Chapter 5). 
III.2.3.  Some from early university-firm interactions:  Data from patents 
Some of the fruits of the early collaborations between universities and 
pharmaceutical firms can be found in data on firm-level patenting in the 1930s.  Combining 
data gleaned from original patent documents with the 1930 and 1935 registries of the 
American Chemical Society, we have identified the affiliations of many of the inventors 
listed on the patents granted to the firms in our sample in 1938.  Among the subset of patents 
for which we were able to identify at least one inventor’s affiliation, approximately 13% 
included at least one academic inventor.  (We were able to identify the inventors for 184 of 
the 384 patents we examined.)  Among prominent pharmaceutical firms Abbott, Lilly, and 
Parke-Davis, 50%, 56%, and 67% of patents granted, respectively, included academic 
inventors (when the inventor could be identified in the ACS directory).  Other well-known 
firms with academic inventors include Merck (1 of 8 patents whose inventors could be   24
identified had an academic inventor) and Sharp and Dohme (1 of 1).  Some smaller firms, 
including Ostro Research Labs Lewis Chemical Co, Sonneborn and Sons, Zonite Products 
Corp., and Commercial Solvents Corp. also included academic inventors on their patents, as 
did Monsanto (although for only 2 of 21 patents with identifiable inventors).  While this 
sample is not sufficiently large to derive substantial statistical power, it provides suggestive 
evidence of considerable academic involvement in important research-oriented tasks in 
some pharmaceutical firms as early as 1938. 
 
III.3.  Reciprocal relationships:  Historical evidence of the influence of early 20
th century 
firms on academic science 
In addition to the documented episodes of academic researchers’ roles in nurturing 
the birth and growth of industrial pharmaceutical research, the historical record suggests that 
a number of companies were influential in shaping the evolution of university research 
programs.  The relationships between Merck and Rutgers University and DuPont and the 
University of Delaware appear to be illustrative of this phenomenon. 
Merck’s choice of Rahway, NJ as the location for the plant it built in 1899 –
influenced in part by a board member who owned land in the community (Feldman and 
Schreuder, 1996, p. 856) – proved propitious for nearby Rutgers University.  In the 1930s, 
Merck developed a relationship with microbiologist Selman Waksman of the College of 
Agriculture at Rutgers.  Starting in 1939, Merck agreed to supply assistance for antibiotics 
developed by Waksman, who would assign all ensuing patents to Merck in exchange for a 
2.5% royalty to be paid to Rutgers.  In 1943 Waksman developed streptomycin, a new 
blockbuster antibiotic that was less toxic and more effective (particularly in treating 
tuberculosis) than existing alternatives. Motivated by fear of a public outcry over the   25
monopolization of such an important drug, Waksman and Rutgers convinced Merck to 
relinquish their rights to Waksman’s patents to the Rutgers Research and Endowment Fund, 
which licensed the patent to several competing companies. The Fund collected $12 million 
in royalties from Waksman’s discoveries over the next forty years.  Swann quotes 
Waksman, whose work earned the Nobel Prize for Medicine in 1952, as suggesting that he 
owed more to support from Merck than from Rutgers for the discoveries (Swann, 1988).
14 
The University of Delaware’s relationship with Du Pont proved to be similarly 
beneficial to that institution.  Established in 1802 on the banks of the Brandywine river, in 
part because the location provided easy access to waterpower and an abundant supply of 
willow trees (from which charcoal could be produced), Du Pont was founded long before 
chemical research was widespread in American universities and, consequently, without 
regard to the availability of local academic science.  Nonetheless, Du Pont played an 
important role in the subsequent development of scientific research at the University of 
Delaware through a number of significant gifts from the Du Pont family and other 
individuals associated with Du Pont.  In 1924, the first physics professor was brought to 
Delaware with the help of Lammot Du Pont, who contributed $2,000 for equipment and 
pledged an additional $600 a year for five years, half for research equipment and half to top 
off the new professor’s salary (Munroe, 2004, Chapter 9).  The university’s chemical 
laboratory was established between 1935 and 1937 with a $300,000 gift from Fletcher 
Brown, a former Du Pont Vice President.  Brown also made a donation to supplement the 
salary of Allan Colburn, a Du Pont engineer who became the first professor of Chemical 
Engineering at Delaware in April 1938.  Chemical Engineering quickly became the most 
                                                 
14 Waksman stated that, “Without the help…of an industrial organization that took over a major part of the 
pharmacological evaluation of the antibiotic [streptomycin] and large-scale production our contribution 
would have never attained its goal” (Swann, 1998, p. 90).   26
active field of research at the university, with the possible exception of the agricultural 
experiment station (Munroe, 2004, Chapter 10). 
 
IV.  Data on Universities and Pharmaceutical Research Laboratories, 1920-1946 
We use the historical and mainly qualitative evidence of the preceding section to 
inform and complement a quantitative analysis of the role of academic science in the 
establishment of industrial research labs.  Our analysis takes advantage of data on the 
number of research labs by city over several years from the publication Industrial Research 
Laboratories of the United States, collected by the National Research Council.  In 1920 the 
National Research Council began to circulate surveys inquiring about firms’ industrial 
research activities.  While the term “industrial research” was interpreted broadly to include 
development and product improvement, the term “laboratory” was restricted to apply only to 
those departments of companies that had “separate and permanently established research 
staff and equipment,” excluding “firms that indicated they only occasionally carry out 
research, using teams temporarily recruited for the purpose or assembled from their 
operating staffs” (Industrial Research Laboratories of the United States, 1956, Introduction, 
p. 2).  Government and university laboratories were excluded, as were labs that conducted 
testing and analysis but no research. 
These publications contain information on the characteristics of industrial research 
labs in nineteen years between 1920 and 1985.
15  In the earliest years in which the series was 
published, these characteristics include the firm’s address, the number of its research 
employees, and a brief description of its activities.  In later years, the surveys list the labs’ 
                                                 
15 The years in which volumes were published are: 1920, 1927, 1931, 1933, 1938, 1940, 1946, 1948, 1950, 
1956, 1960, 1965, 1970, 1975, 1977, 1979, 1982, 1983, and 1985.    27
founding dates, number of scientific and other personnel by type (i.e.: biologists, chemists, 
etc.), the names of important researchers, scientific journals published by the lab, and their 
partners in collaborative research.
16  
We combine these data with (a) information on American universities drawn from 
the Bulletin of the Office of Higher Education (Biennial of Education) and the American 
Council on Education’s serial publication American Universities and Colleges
17 and (b) data 
on county-level population and manufacturing establishments drawn from the US censuses 
of population and US censuses of manufacturing, respectively, for the years 1920-1950.
18   
By including population and manufacturing data in the county-level regressions, we control 
for the extent to which the size, magnitude of economic activity, and, to a degree, 
urbanization affect the extent of industrial pharmaceutical research in US counties. 
Figures 4, 5, and 6 plot the industrial research labs, universities, and manufacturing 
establishments, by county on maps of the United States, respectively.
19  The figures suggest 
that manufacturing and industrial research were more concentrated (particularly in the 
manufacturing belt of the Northeast/Midwest) than were population and universities and 
colleges.  Table 2 provides summary statistics from the dataset.  It shows that counties with 
more Ph.D.-granting universities tend to have a much larger number of 
chemical/pharmaceutical industrial research labs per capita, in each year of the sample.  We 
restrict ourselves to data on the number of labs per county in the years 1927, 1938, and 
1946. 
                                                 
16 Starting in 1950, the volumes also contain indices of universities that participate in collaborative research, 
indicating whether or not the university possesses “facilities for research in practically all fields of science”, 
its facilities are limited to specific fields, or it has particular capabilities in certain areas.  
17 We thank Claudia Goldin for making the Biennial data available. 
18 In matching the county-level manufacturing and population data to the county-level lab data, we were 
careful to account for changes over time in county boundaries.  
19 Manufacturing and population are plotted only for those counties above the median for the country.   28
 
V.  Evaluating the Role of Universities as a Determinant of Pharmaceutical 
Laboratory Growth 
Table 3a contains results from panel regressions in which the dependent variable is 
the number of pharmaceutical industrial research labs by county and year.  Because our 
dependent variables are non-negative integers truncated at zero (i.e., count variables), we 
employ Negative Binomial regressions designed to account for these characteristics of the 
data.  To facilitate the interpretation of the coefficients on the covariates as elasticities, each 
of these enters in logs.
20  Each regression includes county population and the number of 
manufacturing establishments in the county to control for factors associated with county size 
and economic composition.  Throughout the Table, we address county-specific 
heterogeneity by controlling for the impact of initial conditions (conditions in the county in 
1927) on the number of laboratories in subsequent years of the data. 
In the first four columns of Table 3a, we model the number of pharmaceutical labs in 
a county as a function of county population, county manufacturing establishments, the initial 
number of pharmaceutical labs in the county in 1927, and, depending on the column, both 
the 1927 count and contemporaneous count of Chemistry or Science-oriented PhDs granted 
by universities in the county.
21  The initial number of pharmaceutical labs in the county 
helps control for county-level heterogeneity, but is also relevant for adjudicating competing 
hypotheses regarding the birth of industrial research labs.  Specifically, the significance and 
direction of the coefficient on initial labs helps evaluate whether their growth is random or 
follows a pattern consistent with convergence or divergence.  This variable enters positively 
and significantly in each of the models.  That implies that counties with more 
                                                 
20 In each case, we add 1 to the variable before taking logs. 
21 These variables are expressed in logs to account for heteroskedasticity.   29
pharmaceutical labs in 1927 had faster rates of growth in labs to 1938 and 1946.  Controlling 
for other relevant factors, this suggests that counties with a larger number of initial 
laboratories are more likely to experience laboratory births in the future, a pattern consistent 
with the divergence hypothesis.  The finding is consistent with the pattern of path dependent 
growth evident in Feldman and Schreuder’s study of the early pharmaceutical industry in the 
Mid-Atlantic region (1996).  Divergence does not appear to be the only significant pattern in 
the data, however. 
To investigate the hypothesis that universities exerted a significant influence on the 
birth of industrial research labs, we employ the number of PhDs awarded in a county as a 
proxy for the extent to which local universities engage in relevant research.
22  In Columns 1 
and 2, we include the number of PhDs awarded in 1927 separately from the number of PhDs 
awarded contemporaneously. In both cases, the contemporaneous number of PhDs is 
positive and significant at the 1% level.  The coefficients in these columns imply that, 
holding observable county characteristics constant, an increase of 10% in the number of 
Chemistry PhDs or overall Science PhDs is associated with a 4.0% and 3.2% increase in the 
number of labs in the county, respectively.  Consistent with the fact that there is a great deal 
of autocorrelation in the geographic distribution of PhD graduates, the impact of 
contemporaneous degrees awarded increases when the controls for initial conditions are 
removed in Columns 3 and 4.  Although we do not report them here, the results obtained 
using county-level data in Table 3a are consistent with estimates we obtained using MSA-
level data.  It is also worth noting that these results are not driven by those counties in which 
                                                 
22 We also obtained data on the universities’ research expenditures for certain years. While this variable comes 
closer to the effect we are trying to estimate, it is not available for every university in every year. As a result, 
we use number of PhD degrees awarded, which is perhaps noisier but we would argue a reasonable proxy for 
the research effort of the university.   30
the largest firms (e.g., such as Abbott, Lilly, and Merck) reside.  The key results in 3a are 
robust to the exclusion of counties that include firms whose R&D employment falls into the 
top 10 percent of the distribution.  The results are also robust to the exclusion of all counties 
in states in New England and the Mid-Atlantic area (i.e., MD, DE, PA, NJ, NY, CT, RI, 
MA, VT, NH, and ME).  
While we would like to model the growth of pharmaceutical employment in addition 
to the number of labs over this period, the NRC data on lab employment are less reliable.  
For example, employment data may reflect total firm employment rather than lab-level 
employment, and, for about 10% of the observations, no employment data are listed.   
Although these data are more noisy, we estimate the correlates of county-level R&D 
workers in Table 3b.  The pattern of divergence evident in the laboratory models remains in 
these models; however, the influence of lagged and contemporaneous PhD graduates is 
statistically insignificant in models that include all of the laboratories in the data (Columns 
1-3).  The number of PhD graduates does enter in a statistically and economically significant 
way, however, in certain models that include only the first laboratory listed for each firm.  
(As a rule, the first laboratory listed is also the headquarters laboratory for the firm.)  In 
Columns 5, the number of contemporaneous Science PhDs enters positively and 
significantly at the 1% level, although the initial number of county Science PhDs is 
statistically insignificant.  The coefficient on contemporaneous Science PhDs suggests that 
10% higher Science PhD graduates is correlated with 90% more laboratory employment in 
the county.  Neither 1927 nor contemporaneous Chemistry PhDs graduates enters 
significantly when both are included in models of county R&D employment (in Column 4); 
however, when the initial number of Chemistry PhDs is omitted (in Column 6), the   31
contemporaneous count is significant at the 1% level.  Considering the noisiness of the lab-
level counts of R&D employment, we interpret these results as suggestive of a relationship 
between proximate academic science and county R&D employment, at least in the case of 
headquarters facilities. 
Table 4 contains the results of conditional fixed-effects Negative Binomial 
regressions run on all years (1927, 1938, and 1946) and including a county-level fixed effect 
to control for time-invariant characteristics of the county that may be associated with both 
the location of R&D and academic science.  The coefficients in Table 4 are thus identified 
by changes over time in the number of PhDs granted and the extent of R&D located in a 
county.  They continue to exhibit a positive and significant association between academic 
research in Chemistry and in science more broadly (with a slightly larger effect coming from 
Chemistry) after controlling for unobserved heterogeneity across counties. 
In this table, we also present estimates that use a distance-weighted count of PhDs 
within a 500 mile radius of the county in which the lab is located.
23  These distance-
weighted counts are calculated by summing up PhDs granted by all universities within 500 











where PhD_wt for firm i is the number of PhDs nearby, weighted by the distance between 
firm  i and university j.  Nearby PhDs would get a very high weight (very low inverse 
weight), whereas PhD 500 miles away make almost no contribution to the count.  We 
calculate these variables and estimate the relationship between them and the R&D variables 
                                                 
23 We thank Toby Stuart for suggesting a distance-weighted measure.  We modeled our PhD count on the “IPO 
concentration” measure found in Stuart and Sorensen (2003).   32
because of concerns about the arbitrary nature of county boundaries.  The fact that M.I.T., 
located in Middlesex county, MA, is a stone’s throw from Boston and Suffolk county means 
that when we use county boundaries to define the radius within which we expect spillovers 
to take place, we will sometimes miss important potential relationships at the boundaries of 
counties.  We use the distance-weighted counts as a robustness check, and find that similar 
results are obtained whether we use county boundaries or a continuous distance-weighted 
measure to define the location of “nearby” academic science. 
It should be noted here that the data on research labs may not be exhaustive of all the 
labs in existence for the early years during which it was collected.  The Appendix to this 
paper reproduces an excerpt from the introduction to the 1927 edition of the series.  It 
explains that members of the main scientific and engineering associations were consulted in 
order to establish a list of firms known to have in-house research labs, and the published 
information is based on surveys were sent to these firms.  It is important to determine what 
effect this sampling bias might have on the results, that is, whether the correlation between 
labs and universities per county could be an artifact of the way the sample was constructed.  
If, for example, regional branches of scientific and engineering associations tended to be 
located near universities, they may have had more information about research labs in the 
surrounding community. To guard against this possibility, we ran regressions that include a 
dummy variable equal to 1 if there was a branch of the American Chemical Society (ACS) 
located in county i in year t.
24  In the event that a bias is introduced by the tendency of ACS 
branches to locate near universities, this dummy will correct for that bias.  Column 5 of 
Table 3a shows that the coefficient in the on the number of chemistry PhDs is slightly 
                                                 
24 These data were obtained from the Directory of Members of the American Chemical Society. Directories 
from 1924, 1930, and 1947 listed the locations of branch headquarters and the year in which they were 
chartered.   33
reduced, but remains significant at the 5% level.  Similar results are obtained for the other 
specifications if the ACS branch dummy is included. 
 
VI.  Mechanisms of university-industry interaction:  Collaboration  
  We look more closely at the role played by proximity to academic science in Table 
5, in which the firm’s decision to collaborate with academic scientists is modeled as a 
function of the extent of research undertaken at nearby universities.  The number of PhDs in 
science or chemistry awarded by local universities is positively and significantly associated 
with the propensity of pharmaceutical firms to engage in collaborative research with 
universities.  Firms with larger numbers of researchers are significantly more likely to 
engage in cooperative research, and older firms are slightly more likely to collaborate with 
academic scientists.
25  We also estimated specifications including the manufacturing or 
population intensities of the county, and these variables were insignificantly associated with 
the probability of collaboration.  To test the hypothesis that collaboration with local 
academic scientists was more important for firms at different stages of the life cycle, we 
include interaction effects of local chemistry research with age and size in columns 4 and 5.  
The coefficient on the interaction of age and nearby PhDs in chemistry is insignificant at the 
5% level.  This is slightly surprising, considering our expectation that younger firms might 
be relatively lacking in internal research capabilities and therefore more likely to benefit 
from collaboration with local scientists.  The effect of local academic chemistry research 
does not appear to vary according to firm size, however, since the interaction of firm size 
and chemistry PhDs is not significant at the 5% level.  
                                                 
25 When the age variable is included, the number of observations falls because age is only observed in the 1946 
sample.   34
 
VII.  Statistical evidence on the influence of private industry on university programs 
Our qualitative evidence suggests that the research needs of large firms played a role 
in the evolution of at least a few universities.  Our quantitative analysis offers mixed support 
for this proposition.  Table 6 reports the results of logit regressions at the level of the 
university that examine the determinants of the adoption of a chemical engineering program 
for the first time between 1937 and 1947.  We use the full sample of universities and 
colleges drawn from the publication American Colleges and Universities, excluding 
religious seminaries, teacher’s colleges, and junior colleges.  Data on engineering programs 
in American universities are drawn from the United States Office of Education’s Bulletins.
26  
The dependent variable takes on the value 1 if the university established a department of 
chemical engineering for the first time between 1937 and 1947, and 0 if not.  Universities 
that had already established programs by 1937 are omitted from the analysis.  This variable 
is regressed on a measure of pharmaceutical research in industry in the county in 1938, the 
population and number of manufacturing establishments in the county in 1940 and 1939 
respectively, and the growth of population, manufacturing, and industrial research in 
pharmaceuticals during the period.
27  The results show that universities located in counties 
that were centers of research in the pharmaceutical industries in 1938 were significantly 
more likely to establish a department of chemical engineering between that year and 1947, 
even after controlling for the growth of the industry during that period.  This appears to be 
evidence of a feedback effect in which the presence nearby firms influenced the programs 
offered by universities.  Such effects were not evident, however, when we looked at 
                                                 
26  The Bulletins, part of the series “Accredited Higher Institutions” were published in 1938 and 1948. 
27 For universities in cities that fall in multiple counties, we use the average of these variables.   35
universities that began granting Ph.D.s in Chemistry during this period.  We were also 
unable to find evidence of “anchor” effects in the data (Agrawal and Cockburn, 2003; 
Feldman, 2003), in which especially large firms had a particularly large impact on the 
growth of local university programs in sciences or chemistry. 
 
VIII.  Instrumental Variables Estimates 
 
Preceding sections of this paper document a statistically significant, positive 
relationship between the number of pharmaceutical industrial research laboratories in a 
county and university research in a county, after controlling for other variables likely to 
influence the location decision of R&D labs and including a county-specific fixed effect.  
These results imply that growth over time in the amount of university research (as measured 
by the number of PhDs granted) in a county was associated with growth over time in 
pharmaceutical R&D in a county.  However, because university research is also likely to 
have been stimulated by nearby industrial research (through consulting contracts, joint 
research projects, demand for graduates, etc.), we cannot necessarily infer a causal 
interpretation from this relationship.  Indeed, the stories of Chemical Engineering at the 
University of Delaware and the streptomycin royalties at Rutgers, together with the results 
presented in Table 6, illustrate the possibility of “feedback effects” from firms to 
universities during this period.  As Geiger observes, “but if the universities were dedicated 
to science, broadly speaking, by the beginning of the twentieth century, it was not yet 
evident that science was or ought to be beholden to universities.  Scientific investigation was 
undertaken in government bureaus and in semi-independent laboratories… [E]ven by 1920   36
the research universities could not be assured of being the primary locus of basic research” 
(Geiger, 1986). 
Panel estimates of the relationship between university and industrial research are 
likely to be characterized by simultaneity – research universities attracted industrial 
laboratories, and the research conducted in these laboratories affected nearby academic 
departments.  In this section, we use instrumental variables to correct for this simultaneity 
bias.  The instruments are the amount of money obtained as the proceeds of the sale of land 
and scrip granted to the state under the Morrill Act of 1862, and a dummy variable equal to 
1 if a university in the county was founded before 1800.  
  The Morrill Act established the “land-grant” colleges by giving the states public 
lands that could be sold and to finance the colleges.  A state received 30,000 acres for each 
member of its congressional delegation, and since the smallest states had at least two 
senators and one representative, the minimum land grant consisted of 90,000 acres.  The 
Hatch Act of 1887 provided funding for agricultural experiment stations, and a second 
Morrill Act in 1890 extended the land grant provisions to southern states. 
  While the amount of land granted under the Morrill Act was proportional to the size 
of the state, the sale price per acre obtained by states varied considerably, and for somewhat 
aleatory reasons.  Nevins (1963) writes that: 
“A great deal of obscurity yet surrounds the precise disposition made by some states of their 
share of the Morrill grant…Many university historians tend to pass over the disposition of 
the grants hastily…partly because the story has occasional elements of folly and rascality 
that make it embarrassing.  A number of states let the land scrip slip through their fingers; 
fingers loosed by negligent officers, pried apart by speculators, or even greased by 
corruptionists” (p. 29). 
Rhode Island was granted 120,000 acres, and asked Rev. Horace T. Love (president of 
Brown University) to select the land for sale.  He went west in the summer of 1863, and   37
came back “to report that the task was impossibly heavy, for it involved choosing lands, 
paying taxes, negotiating sales, and defending titles” and a committee of five was appointed 
by Love to take charge. The committee then sold the land to Love in 1865 for $50,000 (the 
lowest amount received by any state, and the third lowest per acre), accepting payment over 
five years with no interest. Nevins is “not astonished to learn that the sale aroused much 
criticism.”  In Pennsylvania, “Heavy pressure had come from an unholy partnership of land 
speculators, anxious to obtain a bargain, and officers of the state college, anxious to get 
funds for a new start”  Other states in which the sale of Morrill lands was bungled include 
New Jersey, New Hampshire, and Connecticut (all quotes from Nevins, 1963, p. 29-31). 
In contrast, states like New York managed to turn the grants into more significant 
endowments. Faced with a glut of land scrip and depressed land prices following the Act, 
Ezra Cornell purchased New York’s scrip and held it until prices rose.  When Cornell 
returned the land and profits to the university in 1905, the value had risen almost seven-fold, 
to $5,460,038.  California, Illinois, Iowa, Michigan, Minnesota, and Nebraska, also obtained 
higher prices per acre for their scrip.  The appendix lists the acreage granted and amount 
obtained at sale, by land grant institution.
28 
The price per acre obtained for Morrill Act land grants had a long-run impact on 
university finances.  The states that obtained the most for their scrip are the ones that are 
even today home to the better-funded public universities.  However, because the price per 
acre obtained by the states varied substantially for reasons unrelated to the state’s 
attractiveness to industrial research labs seventy years hence, it constitutes a valid 
instrument.  
                                                 
28 These data come from the U.S. Office of Education’s Biennial of Higher Education, 1928.   38
The instruments vary by county – they equal zero for all counties not containing a 
public university.  There may be some concern that states placed universities in counties 
with heavy manufacturing concentration, and that for this reason the land grant instrument is 
correlated with the errors.  While it is true that states had a mandate to serve agricultural and 
manufacturing interests through public universities, we feel that this concern is misplaced 
because any influence the location of manufacturing in the mid- to late-nineteenth century 
may have had on the location of public universities is controlled for through the inclusion in 
the regression of the number of manufacturing establishments in the county.  
  Table 7a presents results of a two-stage least squares (2SLS) model in which the 
endogenous variable is log of the number of PhDs granted in a county, and the instruments 
are the original sale price received by states for land and scrip obtained through the Morrill 
Act and the dummy for universities founded before 1800.  Two sets of regressions results 
are included, one with the log of the number of labs on the left hand side, and another with 
the log of R&D employment.  We control for manufacturing, population, and year and 
region fixed effects (county or state fixed effects could not be included due to collinearity 
with the instruments).  The relationship between university research in a county and 
pharmaceutical R&D is positive and significant at the 5% level after instrumenting, whether 
research is proxied by Chemistry PhDs or Science PhDs.  The first-stage F-statistic (from 
the regression of the endogenous variable on the instruments) is 64.4 for chemistry and 76.3 
for science.  These values are well above the “rule-of-thumb” F-statistic of 10 proposed by 
Staiger and Stock (1997) as a test for weak instruments. 
  To be consistent with the rest of the estimates in the paper, which use the Negative 
Binomial model to account for the discrete, non-negative nature of the dependent variable,   39
Table 7b presents non-linear two-stage least squares estimates obtained using the 
Generalized Method of Moments (GMM).
29  The GMM estimates remain positive and 
significant at the 5% level when the left-hand-side variable is the number of labs.  However, 
when we estimate the causal effect of local academic science on R&D employment in the 
county, the effect is not significant.  We also tried estimating the IV models with distance-
weighted PhDs on the right-hand-side, and obtained similar results – a positive, significant 
effect of science or chemistry PhDs when the dependent variable is the number of labs, but a 
positive, insignificant effect when the dependent variable is lab employment.  The 
instruments are also equally valid when we use distance-weighted PhDs. 
How do the effects compare to the un-instrumented effects displayed in Table 4?  In 
the fixed-effects Poisson estimates, the elasticity of the number of labs with respect to the 
number of Chemistry PhDs is 0.450, implying that a 10% increase in the number of 
Chemistry PhDs awarded in a county is associated with a 4.5% increase in the number of 
pharmaceutical research laboratories nearby, controlling for county-specific fixed effects.  
After instrumenting, the elasticity of labs with respect to Chemistry PhDs found in the 
GMM estimates in Table 7b is 0.325.  The elasticity with respect to science PhDs sees a 
similar reduction from 0.342 to 0.224. 
 
IX. Discussion 
  The 1920s, 30s, and 40s saw the diffusion of an organizational innovation in the 
form of the in-house R&D laboratory in the United States.  Also during this period, the 
modern American research university developed and collaborative linkages emerged 
                                                 
29 See Mullahy (1997) for an example of a GMM model for count data with endogenous regressors.   40
between industrial and academic researchers.  We argue that universities played an 
important role in the emergence of industrial research situated within the boundaries of the 
firm, and we present evidence that R&D labs located near universities benefited from 
increased access to academic scientists and graduates.  The results described in this paper 
characterize the relationship between universities and the pharmaceutical industry between 
1927 and 1946.  They demonstrate that industrial and academic research were co-located, 
and that proximity to university research was associated with a greater likelihood that firms 
adopt industrial research facilities and collaborate with academic scientists. 
Our qualitative and quantitative analyses provide evidence consistent with the 
possibility of feedback effects, according to which university programs were affected by the 
presence of pharmaceutical industry activity.  Specifically, our empirical results suggest that 
universities located near larger numbers of industrial research labs in chemistry and 
pharmaceuticals as of 1938 were more likely to establish new programs of chemical 
engineering by 1946. 
In an attempt to identify the causal effect of academic science on the growth of 
industrial research, we employ an instrumental variables approach to correct for simultaneity 
bias in our estimates of the impact of university research on the birth of industrial research 
laboratories.  In sum, our analyses suggest that while the presence of industrial facilities 
helped shape the direction of university research programs, there was a significant, positive, 
and causal effect running from university research to the growth of industrial research 
laboratories in the first half of the twentieth century in the United States.   41
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Table 1: Pharmaceutical Research Labs and Academic Collaborators, 1938 
 
Laboratory  Location University   
Bauer and Black  Chicago, IL  Northwestern, U Chicago, U Michigan 
Breon and Company, Inc., 
George A.  Kansas City, MO  U Nebraska, U Kansas, U Cincinnati 
Bristol-Meyers Company  Hillside, NJ  Carnegie Institute  Technology, Rutgers, 
Stanford 
Carbide and Carbon 
Chemicals Corporation 
South Charleston, 
WV  Mellon Institute  Industrial Research 
Commercial Solvents 
Corporation  Terre Haute, IN  Purdue University 
Drackett Company  Cincinnati, OH  Ohio State University 
Emerson Drug Company  Baltimore, MD  U Maryland; U Illinois; Yale 
Endo Products, Inc.  New York, NY  NYU 
Harshaw Chemical Company  Cleveland, OH  Western Reserve University 
Hynson, Westcott, and 
Dunning, Inc.  Baltimore, MD  John Hopkins University, U Maryland 
Jergens Company, Andrew  Cincinnati, OH  University  Cincinnati 
Kessler Chemical Corporation  Philadelphia, PA  Philadelphia College  Pharmacy and 
Science 
LaMotte Chemical Products 
Company  Baltimore, MD  Western Reserve University 
Merck and Company, Inc  Rahway, NJ 
U California; John Hopkins; U 
Pennsylvania; Princeton; NYU; Tulane; 




St. Louis, MO; 
Dayton, OH 
U Cincinnati, U Illinois, Michigan U, U 
Nevada, U Wisconsin, and Princeton 
National Oil Products 
Company, Inc.  Harrison, NJ  Harvard Medical School; U Iowa; 
Lehigh; Columbia 
Sharp and Dohme, Inc  Glenoden, PA and 
Baltimore, MD 
U Pennsylvania, Bryn Mawr College, 
Johns Hopkins Hospital, Philadelphia 
College  Pharmacy and Science; U 
California, Yale,  Northwestern, 
Rochester 
U.S. Industrial Alcohol 
Company 
Stamford, CT and 
Baltimore, MD 
Kalamazoo College, Stanford, Temple, U 
Connecticut, U Chicago, U Detroit, U 
Michigan, U Tennessee 
 
Source: Industrial Research Laboratories of the United States, 1938   45
Table 2a:  Descriptive Statistics 
  Obs Mean  Std.  Dev. Min  Max 
Year  9942 37.02  7.79  27  46.00 
County-Level data         
County Population  
(in hundreds of thousands) 
9304 0.04 0.15  0.000042  4.29 
County Manufacturing Establishments 
(in hundreds) 
9304 0.72 5.12  0  263.28 
Pharma laboratories  9304 0.07 0.60  0  28.00 
R&D personnel  9304 2.20  33.86  0  1712.00 
Patents  9304 0.13 4.02  0  236.00 
Cooperative arrangements with 
universities 
9304 0.02 0.43  0  28.00 
Count of Universities  9304 0.04 0.28  0  6.00 
PhDs granted in Science  
(continuous distance measure) 
9318 1.58 2.33  0  40.08 
PhDs granted in Chemistry (continuous 
distance measure) 
9318 0.58 0.86  0  17.57 
PhDs granted in Science in County  9304 0.59 6.33  0  146.91 
PhDs granted in Chemistry in County  9304 0.21 2.20  0  44.45 
Firm-Level data         
R&D personnel  631 28.10 66.27  0  825.00 
Year firm founded  
(only available for 1946 data) 
39 1886.03  31.31  1828 1924.00 
Firm Age  
(only available for 1946 data) 
631 10.68 19.13  0  118.00 
Patents received  625 1.51 9.88  0  118.00 
Cooperative Agreement with University  
(not available for 1927 data) 
392 0.54 0.50  0 1.00 
University-Level data         
Total PhDs granted  342 16.97 29.23  0  171.55 
PhDs granted in Science  342 12.58 19.92  0  105.91 
PhDs granted in Chemistry  342 4.60 7.32  0  43.45 
 
Table 2b:  Pharmaceutical labs per 100,000 population 
 Obs  Std.  Dev.  Mean 
Counties without a PhD-granting university 
1927 3048  0.066  0.383 
1938 3015  0.033  0.423 
1946 2997  0.054  0.672 
      
Counties with a PhD-granting university  
1927 59  0.746  1.615 
1938 84  0.762  1.986 
1946 101  1.040  1.969 
      
Counties with a university granting PhDs in Chemistry 
1927 48  0.729  1.647 
1938 73  0.836  2.095 
1946 90  1.056  1.928   46
Table 3a:  Location of pharmaceutical research, 1938-1946 
Negative Binomial regressions, controlling for initial conditions 
 
 (1)  (2)  (3)  (4)  (5) 
0.401     0.555  0.310 
Chemistry PhDs in county
† 
(0.122)***    (0.156)***  (0.123)** 
0.227       0.318 
1927 Chemistry PhDs in county
 † 
(0.261)       (0.219) 
 0.318  0.416     
Science PhDs in county
† 
 (0.096)***  (0.121)***     
 0.132       
1927 Science PhDs in county
† 
 (0.153)       
2.307 2.312  2.327  2.327  2.177 
1927 Pharma Labs in county
† 
(0.176)*** (0.178)***  (0.181)*** (0.182)*** (0.160)***
-2.273 -2.281  -2.329  -2.321  -2.458 
Population
† 
(0.578)*** (0.573)***  (0.574)*** (0.577)*** (0.548)***
0.804 0.803  0.809  0.807  0.788 
Manufacturing
† 
(0.077)*** (0.077)***  (0.076)*** (0.077)*** (0.074)***
       0.625 
ACS section 
      (0.205)***
-0.947 -0.949  -0.941  -0.935  -0.918 
Year = 1938 
(0.169)*** (0.167)***  (0.166)*** (0.167)*** (0.157)***
-6.121 -6.122  -6.152  -6.142  -6.125 
Constant 
(0.297)*** (0.295)***  (0.292)*** (0.294)*** (0.264)***
Observations 6197  6197  6197  6197  6197 
Log Likelihood  -833.44  -834.48  -835.06  -834.38  -831.95 
† in logs 
Robust standard errors in parentheses;  * significant at 10%; ** significant at 5%; *** significant at 1%   47
Table 3b: Location of R&D, dependent variable = laboratory employment in county i in year t 
 
  (1) (2) (3) (4) (5) (6) 
  Using all labs  Using only first lab listed 
-0.578   0.077  0.930    1.302    
Chemistry PhDs in county
† 
(0.505)   (0.214)  (0.590)   (0.406)***
1.005     0.630    
1927 Chemistry PhDs in county
 † 
(0.683)     (0.543)    
 -0.087     0.919   
Science PhDs in county
† 
 (0.296)     (0.324)***  
 0.278     -0.090   
1927 Science PhDs in county
† 
 (0.380)     (0.298)   
1.117 1.114 1.117 1.009 1.032 1.023    
1927 R&D Workers in county
† 
(0.159)*** (0.158)*** (0.155)*** (0.252)*** (0.249)*** (0.247)***
0.257 0.211 0.210  -2.274 -2.324 -2.300    
Population
† 
(2.699) (2.711) (2.722) (2.030) (2.027) (2.023) 
1.116 1.118 1.125 1.615 1.620 1.619    
Manufacturing
† 
(0.206)*** (0.208)*** (0.205)*** (0.213)*** (0.212)*** (0.211)***
-3.782 -3.772 -3.771 -1.848 -1.847 -1.845    
Year = 1938 
(0.449)*** (0.447)*** (0.446)*** (0.483)*** (0.483)*** (0.482)***
-2.562 -2.576 -2.593 -5.922 -5.939 -5.933    
Constant 
(0.774)*** (0.778)*** (0.766)*** (0.823)*** (0.820)*** (0.818)***
Observations  6197 6197 6197 6197 6197 6197 
Log  Likelihood  -2373.00 -2373.24 -2373.33 -1848.2039 -1848.32 -1848.48 
 
† in logs 
Robust standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1%   48
Table 4: Conditional Fixed Effects Negative Binomial Regressions, 1927, 1938 and 1946 
 
Dependent variable is either the number of laboratories in county i in year t, or the total employment 
of laboratories in the county. 
 
(1)  (2)  (3) (4) (5) (6) 






0.342           Science PhDs in 
county
†  (0.150)**          
 0.450    0.145      Chemistry PhDs in 
county
†   (0.181)**    (0.104)     
       0.038    Chemistry PhDs in 
county         (0.012)***   
   0.188      0.186  Distance-weighted 
Chemistry PhDs     (0.065)***     (0.053)***
-3.690 -3.617  -2.042  0.624  0.471  0.414 
Population
† 
(1.337)*** (1.337)*** (1.566)  (0.607)  (0.623)  (0.630) 
0.436 0.446  0.257  0.532  0.529  0.460 
Manufacturing
† 
(0.272) (0.272)  (0.270)  (0.127)*** (0.127)***  (0.128)***
2.237 2.121  2.597  -5.507  -5.428  -5.261 
Constant 
(1.702) (1.690)  (1.789)  (0.603)*** (0.600)***  (0.596)***
Observations  788  788  781 644 644 640 
Number of groups 
(county state)  257  257  255 209 209 208 
Log Likelihood  -411.70  -411.18  -404.82  -821.30  -817.68  -812.79 
 
† in logs  
Year dummies included 
Standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1%           
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Table 5 Determinants of Cooperative Research 
 
Logit estimates 
Dependent variable: COOP = 1 if firm has cooperative agreement with University  
 
 (1)  (2)  (3)  (4)  (5) 
Science PhDs
† 0.376***         
 (0.061)         
Chemistry PhDs
†   0.503  0.652  0.517  0.574 
   (0.084)***  (0.135)***  (0.221)**  (0.235)** 
R&D staff
† 0.186**  0.177  -0.005  -0.005  0.181 
 (0.082)  (0.082)**  (0.103)  (0.104)  (0.084)** 
Age       0.011  0.008   
     (0.006)*  (0.007)   
Age X chemistry PhDs
†       0.005   
       (0.006)   
R&D
† X chemistry PhDs
†         -0.015 
         (0.045) 
Year = 1946  1.495***  1.474      1.485 
 (0.274)  (0.273)***      (0.276)*** 
Constant -2.158***  -2.090  -0.364  -0.301  -2.115 
 (0.310)  (0.305)***  (0.358)  (0.378)  (0.322)*** 
Observations 528  528  351  351  528 
Log likelihood  -319.17  -319.75  -220.11  -219.87  -319.70 
 
† in logs 
Robust standard errors in parentheses           
* significant at 10%; ** significant at 5%; *** significant at 1%             50
Table 6: New Chemical Engineering programs, 1937-47 
 
Dependent variable = 1 if the university began offering degrees in chemical engineering 
between 1937 and 1947 
  
  (1) (2) (3) (4) 
Pharma labs in 1938  0.249  0.285     
 (0.113)**  (0.115)**     
Pharma R&D employment in 1938      0.008  0.009 
     (0.004)**  (0.004)** 
Manufacturing in 1939   0.004  -0.273  -0.045  -0.393 
  (0.460) (0.514) (0.469) (0.536) 
Population  in  1940  -0.187 0.171  -0.023 0.364 
  (0.609) (0.643) (0.604) (0.651) 
Growth of Population, 1940-1950    1.638    1.531 
   (1.092)   (1.117) 
Growth of Manufacturing, 1939-
1947   -0.817   -1.044 
   (0.642)   (0.647) 
Growth of pharma labs, 1938-1946    -0.265     
   (0.137)*     
Growth in R&D employment, 
1938-1946      -0.000 
      (0.002) 
Constant  -1.429 -4.261 -3.005 -5.834 
  (4.916) (5.135) (4.845) (5.134) 
Observations  867 867 867 867 
 
Robust standard errors in parentheses           
* significant at 10%; ** significant at 5%; * significant at 1% 
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Table 7a: 2SLS instrumental variables estimates 
  (1) (2) (3) (4) 
  Number of labs
†  Number of labs







†  0.083   0.162  
 (0.038)**    (0.110)   
Science PhDs
 †   0.055   0.113 
   (0.025)**   (0.073) 
Population
†  1.350 1.356 3.339 3.340 
  (0.143)*** (0.142)*** (0.387)*** (0.385)*** 
Manufacturing
†  -0.009 -0.009 -0.009 -0.009 
 (0.003)***  (0.003)***  (0.009)  (0.009) 
Constant  0.037 0.039 0.027 0.030 
 (0.009)***  (0.009)***  (0.031)  (0.031) 
Observations 9304 9304 9304 9304 
First-stage F stat  64.4  76.29  64.4  76.29 
Over-id test stat  1.458  1.613  0.006   0.000 
p-value  0.227 0.204 0.939 0.989 
 
Table 7b: GMM (non-linear 2SLS) instrumental variables estimates 





 † 0.326***    0.298   
  (0.136)   (0.405)  
Science PhDs
 †   0.225**   0.240 
   (0.097)   (0.260) 
Manufacturing
† 0.827*** 0.820*** 0.830*** 0.831*** 
  (0.097) (0.096) (0.155) (0.151) 
Population
†  -0.258 -0.212 -0.479 -0.535 
  (0.407) (0.3919)  (0.935) (0.863) 
Constant  -5.776*** -5.733*** -3.483*** -3.481*** 
  (0.460) (0.454) (0.774) (0.755) 
Observations 9304 9304 9304 9304 
Over-ID test  0.247   0.192   1.461  1.359  
p-value   0.619  0.661   0.227  0.244 
 
† in logs.  Year dummies included. Robust standard errors in parentheses         
* significant at 10%; ** significant at 5%; *** significant at 1%   
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Appendix A: Introduction from the 1927 National Research Council survey 
 
“The continued demand for information regarding industrial research laboratories has made 
it seem advisable to issue a second revision of the list originally published in Number 2 and 
revised in Number 16 of the Bulletin of the National Research Council.  The original 
publication, compiled in 1920 by Mr. Alfred D. Flinn, Secretary of the Engineering 
Foundation, listed about 300 industrial laboratories.  The first revision prepared in August 
1921, by Miss Ruth Cobb of the Research Information Service, listed 526 laboratories.  The 
present revision contains data for 1,000 laboratories. 
  As in the earlier lists, all information given in this publication has been obtained 
directly by correspondence and statements are based upon information supplied by 
laboratories….In preparing the mailing list of new companies to which questionnaires 
should be sent, the Research Information Service sought the cooperation of the secretaries of 
the local divisions of the American Chemical Society, the American Institute of Electrical 
Engineers, the American Society of Civil Engineers and the American Society of 
Mechanical Engineers; most of the secretaries supplied a list of the industrial laboratories in 
their community…”   53
Appendix B: Data on Morrill Act land grants 
 




number of acres 
of land or scrip 
received Under 
Morrill Act 
original total sale 
price received by 










Cornell U  1863  990,000  1,688,576*  1865  1868 
Michigan  State  1863  240,000  991,673  1855  1857 
Oklahoma Agr and Mech Coll  1890  350,000  835,637** 1890  1891 
U California  1866  150,000  732,233  1868  1869 
Iowa State Coll  1862  240,000  686,817  1858  1859 
U Illinois  1867  480,000  648,442  1867  1868 
U Minnesota  1863  120,000  579,430  1851  1851 
U Nebraska  1867  90,800  560,072  1869  1871 
Montana State Coll  1889  140,000  533,148  1893  1893 
Kansas State Agr Coll  1863  97,682  491,746  1863  1863 
North Dakota Agr Coll  1889  130,000  455,924  1890  1891 
Penn State Coll  1863  780,000  439,186  1855  1859 
U Missouri  1863  330,000  363,441  1839  1841 
Ohio State U  1864  630,000  340,906  1870  1873 
U Wisconsin  1863  240,000  303,594  1848  1849 
Virginia Agr and Mech Coll  1870  300,000  285,000  1872  1872 
U Tennessee  1868  300,000  271,875  1794  1794 
State Coll of Washington  1889  900,000  247,608  1890  1892 
Georgia State Coll Agri  1866  270,000  242,202  1866  1872 
Massachusetts Agr Coll  1863  360,000  236,287  1863  1867 
Alabama Polytechnic  1867  240,000  216,000  1872  1872 
Purdue U  1865  390,000  212,238  1869  1874 
Oregon Agr Coll  1868  90,000  202,113  1855  1865 
Agr Coll Utah  1888  200,000  194,136  1888  1890 
Mississippi Agr & Mech Coll  1866  210,000  188,028  1878  1880 
Colorado Agr College  1879  916,000  185,956  1877  1879 
Louisiana State U  1869  210,000  182,630  1874  1874 
Agr & Mech Coll of Texas  1866  180,000  174,000  1871  1876 
U Kentucky  1863  330,000  164,960  1879  1880 
North Carolina State U  1889  270,000  135,000  1887  1889 
Clemson Agricultural Coll  1868  180,000  130,500  1889  1893 
U Idaho  1890  90,000  129,615  1889  1892 
South Dakota State Coll  1889  160,000  128,804  1881  1884 
U Vermont  1862  150,000  122,626  1781  1801 
U Maine  1863  210,000  116,359  1865  1868 
Rutgers U  1863  210,000  115,945  1766  1771 
U Maryland  1864  210,000  112,504  1856  1859 
U Nevada  1866  90,000  107,363  1873  1874 
West Virginia U  1863  150,000  90,000  1867  1868 
Conn Agr Coll  1862  90,000  83,000  1867  1869 
U Delaware  1867  90,000  83,000  1867  1869 
U Florida  1870  90,000  80,000  1870  1884 
U New Hampshire  1863  150,000  80,000  1866  1868 
U Wyoming  1889  90,000  73,355  1886  1887 
Rhode Island State Coll  1863  120,000  50,000  1888  1890 
Alaska Agr Col & School of Mines  1929  336,000    1922  1922 
U Arizona  1910  150,000    1885  1922 
U Arkansas  1864  150,000    1885  1891 
U Hawaii        1907  1908 
MIT       1861  1865 
New Mexico Coll of Agr & Mech   1898  250000    1889  1890 
* scrip bought by Mr Cornell yielding later through resale $5460038 for institution 
** $103482 cash and $732155 deferred payments on lands sold as of 1916   54
Figure 1:  Founding Dates of Public Universities  























Figure 2:  Founding Dates of Private Universities 
(using data from 1924 Biennial of Education data Sample) 
 
 













































































Figure 3:   Founding Dates of Industrial Research Labs 


























Founding Dates of Chem/Pharma 





































Figure 4: The Location of Industrial Research in the United States, 1927 
(Sizes of circles indicate the number of labs in the city/town) 
 
 
Figure 5: PhD-granting institutions, weighted by degrees granted, 1928-37 
 
 